There is growing evidence that tumor markers can provide valuable diagnostic and
prognostic information in patients with non-small cell lung cancer. Two of the most important …

Abstract Background/Aim: Lung cancer is a frequent and fatal cancer that is difficult to
diagnose in the early stages. CYFRA 21-1 is a serological marker currently used to …

Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in
non-small cell lung cancer. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

Abstract Background The role of Cytokeratin fraction 21-1 (CYFRA 21-1) as a tumour marker
for head and neck cancer is still a matter of research. The aim of the present study was to …

The diagnostic value of the novel tumor marker CYFRA 21-1 in malignant pleural fluid was
assessed in comparison to carcinoembryonic antigen (CEA). CYFRA 21-1 and CEA were …

Background Cytokeratin 19 and its soluble fragment CYFRA have been studied as markers
that may be associated with response to therapy and survival in non–small-cell lung cancer …

Cytokeratin 19 is particularly abundant in carcinoma of the lung. The CYFRA 21-1 assay has
recently been developed for detection of a cytokeratin 19 fragment in serum. In the current …

PURPOSE: This study investigated the preoperative serum levels of CYFRA 21-1 and CEA
as prognostic factors in patients with stage I non-small cell lung cancer. SUBJECTS: This …

Purpose: The prognostic significance of pretreatment serum C-terminus of cytokeratin 19
(CYFRA21-1, CYFRA) status was evaluated in the patients with surgically treated …

Evaluation of serum cyfra21 in patients with pleural effusion - PMC Back to Top Skip to main
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main …